Inhaled insulin (Exubera®)

Assessment Status Assessment process complete
Drug Inhaled insulin
Brand Exubera®
Indication Pfizer submitted a report on the clinical and cost effectiveness of inhaled insulin (Exubera®) versus sub-cutaneous insulin in patients with diabetes mellitus in support of their application for reimbursement under the Community Drug Schemes.
Assessment Process
Full pharmacoeconomic assessment commissioned by HSE 01/04/2006
NCPE assessment completed 01/06/2006